The FDA recently granted the first approved indication for ICB use in breast cancer, with the use of the anti-PD-L1 antibody atezolizumab in combination with nab-paclitaxel for patients with PD-L1+ triple-negative breast cancer (TNBC) (10). Here, CD274 is linked to breast carcinoma.